Hodgkin Lymphoma

Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress

Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress

By

A retrospective evaluation of patients treated at a tertiary cancer center demonstrated that patients with Hodgkin lymphoma experienced periods of actionable distress in survivorship, despite a low overall distress burden.

Cost of Brentuximab Vedotin as First-Line Therapy for Advanced Hodgkin Lymphoma Prohibitive

Cost of Brentuximab Vedotin as First-Line Therapy for Advanced Hodgkin Lymphoma Prohibitive

By

Although brentuximab vedotin offers clinical benefit over bleomycin in first-line treatment of adults with advanced Hodgkin lymphoma, investigators find the drug is not cost-effective.

Newer Hodgkin Lymphoma Regimens Are Less Toxic, But Still Impose Reproductive Risks

Newer Hodgkin Lymphoma Regimens Are Less Toxic, But Still Impose Reproductive Risks

By

A substudy of a multinational study sought to determine the risk to ovarian function with ABVD, AVD, and BEACOPP regimens on ovarian function in women with Hodgkin lymphoma.

Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin

Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin

By

A retrospective study evaluated the efficacy vs pulmonary toxicity of brentuximab vedotin for relapsed or refractory Hodgkin lymphoma in pediatric patients.

Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era

Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era

[Cancer Management and Research] A review of fertility complications induced by chemotherapy and radiotherapy, as well as possible treatment options for HL patients with fertility problems.

Long-term Survival Improving Over Time in Advanced Hodgkin Lymphoma

Long-term Survival Improving Over Time in Advanced Hodgkin Lymphoma

By

A review of SEER data revealed trends in incidence of advanced Hodgkin lymphoma, discrepancies among subgroups, and survival over 3 decades.

Fifth Indication for Brentuximab Vedotin Is a First for cHL Therapy in 40+ Years

Fifth Indication for Brentuximab Vedotin Is a First for cHL Therapy in 40+ Years

By

FDA approval was granted based on findings from the open-label phase 3 ECHELON-1 study.

18F-FDG PET/CT Accurately Identifies Bone Marrow Involvement in Pediatric Hodgkin's Lymphoma

18F-FDG PET/CT Accurately Identifies Bone Marrow Involvement in Pediatric Hodgkin's Lymphoma

By

Researchers conducted a retrospective study to assess 18F-FDG PET/CT vs bone marrow biopsy to detect bone marrow involvement among pediatric patients with Hodgkin lymphoma.

Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma

Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma

By

In a case-control study using PEDS data, researchers determined the impact of inactivity on risk for Hodgkin lymphoma and non-Hodgkin lymphoma.

Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies

Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies

By

A review of management approaches to Hodgkin lymphoma in Europe vs the United States/North America demonstrates that although some differences exist, worldwide studies that would enhance patient outcomes are feasible.

Brentuximab Vedotin and Bendamustine Proves Effective as Second-line Hodgkin Lymphoma Treatment

Brentuximab Vedotin and Bendamustine Proves Effective as Second-line Hodgkin Lymphoma Treatment

By

Patients who received the recommended phase 1 dose of brentuximab vedotin and bendamustine had an overall response of 78%.

A Rare Case of Classical Hodgkin Lymphoma 10 Years After Liver Transplantation

A Rare Case of Classical Hodgkin Lymphoma 10 Years After Liver Transplantation

By

This case describes management of a 61-year-old male with a history of chronic liver diseases and COPD who developed a posttransplant lymphoproliferative disorder 10 years after a liver transplant.

All-Cause Mortality Improved by Advances in Radiotherapy for Hodgkin Lymphoma

All-Cause Mortality Improved by Advances in Radiotherapy for Hodgkin Lymphoma

By

Investigators assessed the impact of advances over time in the treatment of Hodgkin lymphoma on all-cause mortality in patients with Hodgkin lymphoma who received radiotherapy alone or with chemotherapy.

Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin

Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin

By

Study reports that patients with classic relapsed/refractory Hodgkin lymphoma who received nivolumab after ASCT experienced high rates of response regardless of previous history with brentuximab vedotin.

Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors

Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors

By

Hodgkin lymphoma survivors are at higher risk of second cancers, and that risk is even higher in those with a first-degree relative with cancer.

Severe Fatigue Associated With Unemployment in Hodgkin Lymphoma Survivors

Severe Fatigue Associated With Unemployment in Hodgkin Lymphoma Survivors

By

Severe fatigue is associated with unemployment and financial problems in survivors of Hodgkin lymphoma, highlighting the need for clinicians to address fatigue in these patients.

Cancer-related Fatigue Common in Hodgkin Lymphoma Survivors

Cancer-related Fatigue Common in Hodgkin Lymphoma Survivors

By

There is a high incidence of severe acute and persistent cancer-related fatigue in survivors of Hodgkin lymphoma, regardless of tumor stage or treatment.

PET-CT Can Inform Decision to Omit Bleomycin in Hodgkin Lymphoma Treatment to Reduce Toxicity

PET-CT Can Inform Decision to Omit Bleomycin in Hodgkin Lymphoma Treatment to Reduce Toxicity

By

Omitting bleomycin from the treatment regimen for Hodgkin lymphoma in patients with negative findings on an interim PET scan led to a lower incidence of pulmonary toxic effects without significantly lowering treatment efficacy.

Patients With Hodgkin Lymphoma Resistant to Brentuximab Vedotin Have Poor Outcomes

Patients With Hodgkin Lymphoma Resistant to Brentuximab Vedotin Have Poor Outcomes

By

Patients with classical Hodgkin lymphoma who are resistant to the CD30-directed antibody-drug conjugate brentuximab vedotin have poor outcomes.

Early MRI Screening May Reduce Breast Cancer Mortality Among HL Survivors

Early MRI Screening May Reduce Breast Cancer Mortality Among HL Survivors

By

Early MRI-based screening may reduce breast cancer mortality among women treated with radiation therapy for Hodgkin lymphoma.

Model Demonstrates Benefits of MRI Screening for Breast Cancer in Survivors of Childhood Hodgkin Lymphoma

Model Demonstrates Benefits of MRI Screening for Breast Cancer in Survivors of Childhood Hodgkin Lymphoma

By

Female survivors of childhood Hodgkin lymphoma (HL) who received chest radiation can reduce their risk of breast cancer through early screening.

Inferior Outcomes for African Americans With Pediatric Hodgkin Lymphoma

Inferior Outcomes for African Americans With Pediatric Hodgkin Lymphoma

By

African-American pediatric patients with Hodgkin lymphoma still display a considerable survival disparity when compared to their white and Hispanic peers.

Reducing Treatment, Surveillance Barriers May Benefit Young Patients With Lymphoma

Reducing Treatment, Surveillance Barriers May Benefit Young Patients With Lymphoma

By

Identifying and reducing barriers to recommended treatment and surveillance in those at higher risk of mortality is essential.

Adolescent and Young-adult Survivors of Hodgkin Lymphoma May Not Adhere to Follow-up Recommendations

Adolescent and Young-adult Survivors of Hodgkin Lymphoma May Not Adhere to Follow-up Recommendations

By

Within the first year posttreatment, more than half of Hodgkin lymphoma survivors did not receive all recommended care. However, 96% had their recommended oncology visits and 70% had the recommended laboratory tests within the first 5 years.

Second Cancer Risk Persists for Survivors of Hodgkin Lymphoma

Second Cancer Risk Persists for Survivors of Hodgkin Lymphoma

Hodgkin lymphoma survivors have an increased risk of secondary cancer compared with the general population, even for those receiving more recent treatments.

Innovative Radiotherapy Controls Late Effects in Hodgkin Lymphoma in Pediatric and AYA Patients

Innovative Radiotherapy Controls Late Effects in Hodgkin Lymphoma in Pediatric and AYA Patients

By

Radiotherapy is the most effective single modality for local control of Hodgkin lymphoma. Involved site radiotherapy is a recent innovation intended to reduce the risk of late effects—an urgent goal, particularly for adolescent and young adult patients.

Negative PET Scan Post-ABVD: No Need for RT in Advanced Stage Classical Hodgkin Lymphoma

Negative PET Scan Post-ABVD: No Need for RT in Advanced Stage Classical Hodgkin Lymphoma

A PET-guided approach may reduce the need for additional radiotherapy in some patients with advanced classical Hodgkin lymphoma.

PET Can Guide Subsequent Treatment in Advanced Stage Hodgkin Lymphoma

PET Can Guide Subsequent Treatment in Advanced Stage Hodgkin Lymphoma

By

PET deemed safe for use after two cycles of BEACOPPesc chemotherapy for advanced stage Hodgkin lymphoma, according to a recent study.

TARC Confirmed as Biomarker of Response to PET, Brentuximab Vedotin in Hodgkin Lymphoma

TARC Confirmed as Biomarker of Response to PET, Brentuximab Vedotin in Hodgkin Lymphoma

By

TARC levels correlated with PET-normalization in certain patients with Hodgkin lymphoma treated with brentuximab vedotin, a study indicates.

PD-L1, PD-L2 Genetic Alterations Predict Outcome in Classical Hodgkin Lymphoma

PD-L1, PD-L2 Genetic Alterations Predict Outcome in Classical Hodgkin Lymphoma

By

A study has reaffirmed the importance of genetically defined PD-1 mediated immune evasion for patients with Hodgkin lymphoma.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs